Teva Pharmaceutical Industries Limited · TEVA · FY2026 Q3 · Calendar Q4 2026
Teva’s innovative portfolio grows as revenue guidance rises
Teva’s shift toward innovative medicines and biosimilars is showing growth and margin progress, supporting a higher full-year revenue outlook despite a decline in total Q3 revenue. Sustaining that progress depends on launch execution, payer access, and managing pricing pressure.
Earnings scorecard
Reported versus consensusMarket reaction
prior-close to event-session closeAsk FN2 about TEVA FY2026 Q3
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with Q2, the Q3 analysis points to continued strength in AUSTEDO, AJOVY and UZEDY, with the innovative portfolio reported up 33% and gross margin at 58.7%. Total revenue was reported down 2%, while management raised full-year revenue guidance and advanced its neuroscience and biosimilar portfolios.
Guidance delta
Management raised full-year revenue guidance to $16.7–$17 billion and set an operating-margin target of 22.6%–23.1% (27.8%–28.2% excluding IPR&D).
Key takeaways
- Q3 revenue was reported at $4.4 billion, down 2%, as innovative-product growth offset pressure elsewhere.
- Management reported AUSTEDO growth of 21%, AJOVY growth of 61% and UZEDY growth of 96%, and raised full-year guidance for all three.
- The company reported 58.7% gross margin and raised full-year revenue guidance.
- Biosimilars remain a stated growth priority, with 15 products on the market and 16 pipeline assets cited in the analysis.
- The BXCL501 acquisition adds an at-home acute-agitation therapy to Teva’s neuroscience portfolio.
Management priorities
- Grow AUSTEDO, AJOVY and UZEDY and execute the WELTRUZA launch plan.
- Expand biosimilars and progress pipeline programs, including ecopipam, BXCL501 and anti-IL-15.
- Improve margins, reduce debt and continue the transition toward a biopharma-focused portfolio.
Follow TEVA with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeCompany context
Snapshot as of publicationTeva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, and biopharmaceutical products throughout North America, Europe, and various international markets. The company's diverse product range includes sterile items, hormones, potent drugs, and cytotoxic agents, available in numerous forms like tablets, capsules, injectable solutions, inhalable preparations, liquids, transdermal patches, topical ointments, and creams. Additionally, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). The firm prioritizes several key therapeutic domains: central nervous system disorders, pain management, respiratory ailments, and oncology.…
Healthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| PFE Pfizer Inc. | FY2026 Q3 · Calendar Q4 2026 | — | -2.0% | Pfizer raises 2026 guidance as launched portfolio growth offsets longer-term pressures |
| FMS Fresenius Medical Care AG & Co. KGaA | FY2026 Q3 · Calendar Q4 2026 | — | -3.6% | Fresenius Medical Care cuts 2026 outlook as cost and reimbursement pressure persist |
| RVTY Revvity, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +10.8% | Revvity Raises FY2026 Outlook After 7% Q3 Organic Growth |
| WAT Waters Corporation | FY2026 Q3 · Calendar Q4 2026 | — | +3.8% | Waters Raises FY2026 Revenue Outlook as Organic Growth Accelerates |
| HSIC Henry Schein, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +0.0% | Henry Schein raises 2026 EPS outlook as U.S. dental sales grow |
| PHG Koninklijke Philips N.V. | FY2026 Q3 · Calendar Q4 2026 | — | +4.8% | Philips Q3: order momentum and margins improve; outlook held |
Latest beats and misses
Who reports nextBeat on EPS
- RRXFY2026 Q3 · November 3, 2026+41.1% EPS+11.8% move
- UDRFY2026 Q3 · November 2, 2026+340.8% EPS+0.1% move
- VNOMFY2026 Q3 · November 2, 2026+3.9% EPS-2.6% move
- EQH-PAFY2026 Q3 · November 2, 2026+14.5% EPS— move
- WMBFY2026 Q3 · November 2, 2026+0.2% EPS+3.5% move
- TSEMFY2026 Q3 · November 2, 2026+7.5% EPS-6.7% move
Get the TEVA recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-11-03T19:04:52.633594+00:00
- FN2 earnings calendar · 2026-11-03T01:23:13.143323+00:00
- Polygon adjusted daily market bars · 2026-11-03T19:50:45.785997+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-03T19:50:45.783297+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-03. For educational purposes only; not investment advice.